Berkeley Newswire

Berkeley Newswire

Comprehensive Real-Time News Feed for Berkeley, CA.

Results 1 - 12 of 12 for "u:americanbankingnews.com" in Berkeley, CA

  1. Financial Contrast: Dynavax TechnologiesRead the original story w/Photo

    Thursday Jun 14 | AmericanBankingNews.com

    Dynavax Technologies and Sarepta Therapeutics are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Dynavax Technologies has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

    Comment?

  2. Recent Investment Analysts' Ratings Updates for XomaRead the original story w/Photo

    Monday May 28 | AmericanBankingNews.com

    They now have a $27.00 price target on the stock. According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases.

    Comment?

  3. Xoma (XOMA) Rating Increased to Buy at Zacks Investment ResearchRead the original story w/Photo

    May 16, 2018 | AmericanBankingNews.com

    The brokerage currently has a $27.00 target price on the biotechnology company's stock. Zacks Investment Research 's target price would indicate a potential upside of 9.76% from the stock's previous close.

    Comment?

  4. Recent Investment Analysts' Ratings Updates for XomaRead the original story w/Photo

    May 15, 2018 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1 Y with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  5. XOMA (XOMA) Receives Hold Rating from Zacks Investment ResearchRead the original story w/Photo

    Apr 7, 2018 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1 Y with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  6. Investment Analysts' Recent Ratings Changes for XOMARead the original story w/Photo

    Mar 28, 2018 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1 Y with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  7. XOMA (XOMA) Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Feb 21, 2018 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1 Y with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  8. XOMA Corporation (XOMA) Rating Lowered to Hold at Zacks Investment ResearchRead the original story w/Photo

    Nov 2, 2017 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1 Y with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  9. XOMA Corporation (XOMA) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    Oct 17, 2017 | AmericanBankingNews.com

    The firm presently has a $25.00 target price on the biotechnology company's stock. Zacks Investment Research 's price target would suggest a potential upside of 13.43% from the company's current price.

    Comment?

  10. XOMA Corporation (XOMA) Cut to Sell at Zacks Investment ResearchRead the original story w/Photo

    Sep 26, 2017 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1 Y with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  11. XOMA Corporation (XOMA) Raised to Hold at Zacks Investment ResearchRead the original story w/Photo

    Sep 19, 2017 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1 Y with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

  12. Zacks Investment Research Downgrades XOMA Corporation (XOMA) to SellRead the original story w/Photo

    Sep 13, 2017 | AmericanBankingNews.com

    According to Zacks, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1 Y with potential for the treatment of the inflammatory cause of multiple diseases.

    Comment?

Berkeley Job Listings
View or post Berkeley job listings on Topix.
Berkeley Real Estate
News, listings, and foreclosures in Berkeley from Topix.
Berkeley Mortgages
Find mortgage rates in Berkeley on Topix.